Bob Valamehr will become the new CEO of Fate Therapeutics, succeeding Scott Wolchko. Valamehr has experience in developing stem cell platforms and overseeing multiple drug applications. Wolchko will retire at the end of the year but will remain as a strategic advisor.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing